SCHEMBL2643715

SCHEMBL2643715

CCS(=O)(=O)c1cccc(Cl)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.50
TSHR P16473 2/20 0.49
HPGD P15428 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HTT P42858 2/20 0.44
KDM4E B2RXH2 1/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
PTGES2 Q9H7Z7 3/20 0.44
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
ATM Q13315 1/20 0.43
AKR1B1 P15121 1/20 0.42
MEN1 O00255 2/20 0.42
CXCR2 P25025 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8765900 0.83 PSIP1 (0.48) MCOLN3TSHRHPGDALDH1A1HTT
SCHEMBL29707954 0.83 PSIP1 (0.48) MCOLN3TSHRHPGDALDH1A1HTT
SCHEMBL2642877 0.82 PSIP1 (0.39) MCOLN3TSHRHPGDALDH1A1HTT
SCHEMBL2642878 0.80 CXCR2 (0.43) MCOLN3TSHRHPGDALDH1A1HTT
SCHEMBL11406615 0.80 GAA (0.42) HPGDALDH1A1HTTKDM4EKMT2A
SCHEMBL2633428 0.78 MCOLN3 (0.53) MCOLN3TSHRKMT2ALMNAPTGES2
SCHEMBL1248188 0.78 AKR1B1 (0.56) MCOLN3TSHRALDH1A1KMT2ALMNA
SCHEMBL7976427 0.77 ALDH1A1 (0.50) MCOLN3TSHRHPGDALDH1A1HTT
SCHEMBL28530573 0.77 CA12 (0.45) MCOLN3TSHRALDH1A1KMT2ALMNA
SCHEMBL9740376 0.76 TSHR (0.42) MCOLN3TSHRALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-7504391-B2 Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders SCHERING CORPORATION (US) 2009-03-17 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK MCOLN3 4156/4885TSHR 2323/4885HPGD 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.